ERA-EDTA Symposium 2018

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ESC Congress 2018

Resverlogix is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics?

Agenda

15:30 - 15:35 (local time): Introduction. Ulrich Laufs, MD – Leipzig, Germany.

15:35 - 15:50: The real residual risk in patients with CVD & diabetes: The promise of epigenetics. Erik Stroes, MD – Amsterdam, Netherlands.

15:50 - 16:10: Understanding epigenetics: The potential rationale for BET inhibition in management of CVD. Jorge Plutzky, MD – Boston, USA.

16:10 - 16:25: A clinical view on BET inhibition in targeting residual risk in CVD and diabetes. Kausik Ray, MD.

16:25 – 16:30: Discussion & summary. Co-Chairmen: Kausik Ray, MD and Ulrich Laufs, MD.

Symposium presentations and videos will be posted to the Company website HERE once available.

Event Flyer: /upload/media_element/attachments/42/ESC 2018 Epigenetics Symposium.pdf